(R)-2-(benzo[b]thiophen-5-ylmethanesulfonylamino)-3-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-N-hydroxy-propionamide | 348080-51-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: (R)-2-(benzo[b]thiophen-5-ylmethanesulfonylamino)-3-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-N-hydroxy-propionamide
• 英文别名: (2R)-2-(1-benzothiophen-5-ylmethylsulfonylamino)-3-(1,3-dioxoisoindol-2-yl)-N-hydroxypropanamide
• CAS: 348080-51-3
• 化学式: C₂₀H₁₇N₃O₆S₂
• 分子量: 459.503
• InChiKey: MJYLCZKJMUZIBF-MRXNPFEDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  170
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives
  申请人：——

  公开号：US20030199571A1

  公开（公告）日：2003-10-23

  Compounds of formula (I) wherein R is hydrogen, alkyl alkenyl, alkynyl, aryl, heteroaryl or heterocyclyl; and R 1 is bicyclyl or heterobicyclyl; are useful in the treatment and prophylaxis of conditions mediated by s-CD23 or TNF.

  式（I）中的化合物，其中R是氢，烷基烯基，炔基，芳基，杂芳基或杂环烷基；R1是双环烷基或杂双环烷基；在通过s-CD23或TNF介导的疾病的治疗和预防中是有用的。
• (Hetero) bicyclymethanesulfonylamino-substituted hydroxamic acid derivates
  申请人：SmithKline Beecham p.l.c.

  公开号：US20040225006A1

  公开（公告）日：2004-11-11

  Compounds of formula (I) wherein R is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl or heterocyclyl; and R 1 is bicyclyl or heterobicyclyl; are useful in the treatment and prophylaxis of conditions mediated by s-CD23 or TNF. 1

  式(I)的化合物中，其中R为氢、烷基、烯基、炔基、芳基、杂芳基或杂环基；而R1为双环烷基或杂双环烷基；可用于治疗和预防由s-CD23或TNF.1介导的疾病。
• (HETERO)BICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES
  申请人：SmithKline Beecham plc

  公开号：EP1244616A1

  公开（公告）日：2002-10-02
• [EN] (HETERO)BICYCLYMETHANESULFONYLAMINO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES<br/>[FR] NOUVEAUX COMPOSES ET PROCESSUS
  申请人：SMITHKLINE BEECHAM PLC

  公开号：WO2001047874A1

  公开（公告）日：2001-07-05

  Compounds of formula (I) wherein R is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl or heterocyclyl; and R1 is bicyclyl or heterobicyclyl; are useful in the treatment and prophylaxis of conditions mediated by s-CD23 or TNF.